ArticleScientific reports2025
Trace element imbalances in selenium and mercury in relation to mammographic density and breast cancer progression: a case‒control study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer remains the most prevalent malignancy among women worldwide. Emerging evidence suggests that trace elements, particularly selenium (Se) and mercury (Hg), may contribute to breast cancer pathogenesis. This study aimed to evaluate whether variations in Se and Hg levels in biological matrices are associated with breast cancer stage, related hematological changes and mammographic density. A case-control study was conducted including 285 histologically confirmed breast cancer patients and 215 age-matched controls. Biological samples (scalp hair and blood) were analyzed via atomic absorption spectrometry. Normality was tested (Shapiro-Wilk); parametric (t test, ANOVA) or nonparametric (Mann-Whitney U test, Kruskal-Wallis) tests were applied accordingly, with Tukey/Dunn post hoc corrections. Compared with controls, breast cancer patients presented significantly lower Se levels and higher Hg levels across all stages. For example, the Se concentration in Stage IV hair was 0.25 µg/g (95% CI 0.23-0.27) and that in control hair was 1.59 µg/g (95% CI 1.54-1.64) (t = - 46.2, p < 0.001; Hedges g = - 5.12). The hair Hg concentration was 4.31 µg/g (95% CI 4.24-4.38) vs. 1.19 µg/g (95% CI 1.17-1.21) (t = 84.7, p < 0.001; Hedges g = + 7.05). The blood Se concentration decreased progressively from 220.0 ± 8.2 µg/L in the controls to 51.3 ± 5.8 µg/L in Stage IV (p < 0.001), whereas the blood Hg concentration rose from 0.97 ± 0.05 to 2.94 ± 0.11 µg/L (p < 0.001). Hemoglobin levels also decreased with stage (12.7 ± 1.2 g/dL for controls vs. 5.62 ± 0.38 g/dL for Stage IV patients, p < 0.001). These findings demonstrate a consistent association between low Se and high Hg levels and advanced breast cancer stage and hematological decline. Notably, Se levels fell below the 70 µg/L GPx3 sufficiency threshold, whereas hair Hg levels exceeded the 2 µg/g toxicological guidance threshold, underscoring the clinical relevance of Se. While causal inference is limited, these results suggest that Se and Hg imbalances may serve as biomarkers for progression. These findings should be interpreted in light of international data where Se deficiency is rare, highlighting population-specific risks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.